Archive for January, 2009
More Velcade-Style Risk-Sharing in the UK?
Submitted by THE HEALTH ECONOMICS BLOG
via the IN VIVO Blog by Melanie Senior on 21/01/09
It appears that Janssen-Cilag feels a lot better now about its pay-for-performance scheme around multiple myeloma drug bortezemib (Velcade) than it did when the program was introduced in 2007.
The Velcade Response Scheme (VRS) came about out of desperation: cost-effectiveness watchdog NICE [...]
NICE to put QALY under examination
Submitted by THE HEALTH ECONOMICS BLOG
LONDON, Jan 27 (APM) - NICE on Tuesday announced an arms-length investigation into how it values health technology, potentially putting the quality-adjusted life year (QALY) under the microscope.
In a press release, the cost-effectiveness body said NICE chairman, Professor Mike Rawlins, has written to England’s top health minister announcing a “short [...]
Wales sidesteps NICE recommendation on kidney cancer drug access
Submitted by THE HEALTH ECONOMICS BLOG
Scrip
Welsh patients will be able to receive four kidney cancer drugs that have not been
recommended by the National Institute for health and Clinical Excellence (NICE), the
Welsh health minister Edwina Hart has announced.
The decision will allow greater access to four drugs currently being reviewed by NICE
for advanced renal cancer - Pfizer’s [...]
‘Comparator Report on Patient Access to Cancer Drugs in Europe’ reveals significant inequalities still remain
Submitted by THE HEALTH ECONOMICS BLOG
Brussels, 16th January 2009 – European patients still face unequal access to cancer treatment, depending on where they live. This was confirmed in a report published today by Dr Nils Wilking, clinical oncologist at the Karolinska Institutet in Stockholm, Sweden, and Prof Bengt Jönsson, Professor of Health Economics at the [...]
The best unknown biotech in the world. Bar none.
Submitted by Bapcha’s Stocks
If I told you that there is a Swiss Biopharmaceutical Company that has an enviable success record that even Genentech would be proud of; that it was founded in 1997; has revenues in excess of a billion dollars a year; gross margins in the high 80’s; and that their stock has not [...]
Oncology Market Access Conference, April 22nd-23rd Zurich
Submitted by THE HEALTH ECONOMICS BLOG
eyeforpharma hosts the 2009 Oncology Market Access conference on 22nd-23rd April in Zurich. I have been told by the organizer that the conference is looking to be very popular. The website and brochure for the conference have been updated, please take a look.
Rating 3.00 out of 5
[?]
New rules on drugs will not increase access for terminally ill: expert
Submitted by THE HEALTH ECONOMICS BLOG
New rules issued by the NHS drugs rationing body to increase access to drugs for terminally ill people will not work, an expert has said.
by Rebecca Smith, Medical Editor, Telegraph
The National Institute for health and Clinical Excellence (Nice) has told its drugs appraisals committees to be more flexible and approve [...]
France to increase cost benefit assessments of new medicines
Submitted by THE HEALTH ECONOMICS BLOG
France’s HAS three-year plan includes economic assessment
Scrip
France’s HAS, an agency set up three years ago to advise the government on healthcare
issues, has set out a three-year work programme for 2009-11 that emphasises its dual
economic and scientific roles. The agency was reorganised last year and set up a new medico-economic committee [...]
